May 18 - 22 Performance (IBio Inc., Microvision, Fuel Cell Energy, more)

Here are some metrics and notes for the fund's activity during May 18 - 22.

Security/ Project	Type	Date of Purchase	Cost of Investment	Current Value	Return %
Hive Blockchain	Stock	4/16/2020	$0.16	0.26	62.50%
Social Capital	Stock	5/1/2020	$10.20	10.6	3.92%
Fuel Cell Energy	Stock	5/3	$2.01	1.98	-1.49%
Microvision	Stock	5/18	$0.93	0.98	5.38%

- The fund sold its stock in IBio as the value of the investment increased over 60%.

- A position has been started in Microvision again at $0.93. A link to the story is here.
- More shares of Fuel Cell Energy have been purchased.



**All posts on this blog are information and opinions only. They are not to be considered recommendations to buy or sell any security. Please do your due diligence first before trading and investing. Please direct all questions and comments to the blog, kdkfund@gmail.com, or on twitter @kdkfund.

Microvision Stock Purchased

This week, the fund has started a position in Microvision. We believe the stock of the company has the opportunity to reach $2.00 before the end of the year. Some notes are below.

- The company had a good conference call on May 7th.

- One of the company's products was also found in Microsoft's Hololens 2. The link to that story can be found here. 

- The company is still using Craig-Hallum Capital Group LLC as a financial advisor.


**All posts on this blog are information and opinions only. They are not to be considered recommendations to buy or sell any security. Please do your due diligence first before trading and investing. Please direct all questions and comments to the blog, kdkfund@gmail.com, or on twitter @kdkfund.

May 11-15 Performance (Crispr, Fuel Cell, Hive Blockchain, Ibio)

Here are some metrics and some notes for May 11-15.

Metrics

Security/ Project	Type	Date of Purchase	Cost of Investment	Current Value	Return %
Hive Blockchain	Stock	4/16/2020	$0.16	0.27	68.75%
Social Capital	Stock	5/1/2020	$10.20	10.52	3.14%
Fuel Cell Energy	Stock	5/3	$2.04	1.84	-9.80%
Ibio	Stock	5/11	$0.99	1.48	49.49%

Notes

- The fund sold its stake in Crispr. The link to the post explaining why we sold can be found here.

- A new stake in Ibio Pharma was started on Monday. The link explaining its purchase can be found here.  Surprisingly, it is getting to a valuation where a sale might occur.

- Some of the proceeds of the Crispr sale went to purchase more shares of Fuel Cell.


**All posts on this blog are information and opinions only. They are not to be considered recommendations to buy or sell any security. Please do your due diligence first before trading and investing. Please direct all questions and comments to the blog, kdkfund@gmail.com, or on twitter @kdkfund.

IBIO Stake Started

The fund has started a stock position in biotech firm Ibio Inc.. The company's mission is " developing therapeutics and vaccines for the betterment of human and animal health" and has a patented plant based testing system named Fastpharming. The fund believes Ibio is positioned well during this time of epidemic and has experience with its previous work on SARS. They have connections all around the world and a first class facility in Bryan, Texas. 

Technically, the stock price is leveling at $1.00 with a lot of room to run.  There will likely be a short term move to 2.00 with any positive news and to $300 or above on positive revenue news. We believe this will happen in the next 6 months.


**All posts on this blog are information and opinions only. They are not to be considered recommendations to buy or sell any security. Please do your due diligence first before trading and investing. Please direct all questions and comments to the blog, kdkfund@gmail.com, or on twitter @kdkfund.

Sold Crispr Stake

The fund has sold its stake in Crispr for $60.25. Reasons for the sale are below. We still believe in the valuable work in Crispr. It is more a financial decision than anything else. We will continue to monitor its progress.

- Crispr hit a target of $60.00 far quicker than the fund believed could happen.
- Other opportunities within the biosciences sector have been found.



**All posts on this blog are information and opinions only. They are not to be considered recommendations to buy or sell any security. Please do your due diligence first before trading and investing. Please direct all questions and comments to the blog, kdkfund@gmail.com, or on twitter @kdkfund.

May 4-8 Performance (Crispr, Microvision, Hive Blockchain, Social Capital, Fuel Cell Energy)

Here are some metrics and notes for the week of May 4-8.

Security/Project	Type	Date of Purchase	Cost of Investment	Current Value	Return %
Crispr Therapeutics	Stock	3/23/2020	$38.78	53.81	38.76%
Hive Blockchain	Stock	4/16/2020	$0.16	0.33	106.25%
Social Capital	Stock	5/1/2020	$10.20	10.34	1.37%
Fuel Cell Energy	Stock	5/3	$1.93	2.1	8.81%

- Sold position in Microvision. Story link here.
- Started position in Fuel Cell Energy. Story link here.
- Bitcoin is back around $10,000 with halving coming up later this month (affecting Hive Blockchain position). 



**All posts on this blog are information and opinions only. They are not to be considered recommendations to buy or sell any security. Please do your due diligence first before trading and investing. Please direct all questions and comments to the blog, kdkfund@gmail.com, or on twitter @kdkfund.

Purchased Shares of Fuel Cell

The fund has purchased shares of Fuel Cell Energy. We purchased the shares for $1.93. We do not have a plan to sell the shares.

Fuel Cell Energy has a mission of  "Delivering clean innovative solutions for the global supply, recovery and storage of energy.".

We are excited to own shares of this company as it is providing an innovative, tested, valuable process that can help with climate change.  We believe the new management is starting to execute on its plans. They have strong partners both domestically, and internationally. The market is wide open with opportunity. 




**All posts on this blog are information and opinions only. They are not to be considered recommendations to buy or sell any security. Please do your due diligence first before trading and investing. Please direct all questions and comments to the blog, kdkfund@gmail.com, or on twitter @kdkfund.
 

Sold Remaining Microvision Shares

With some surprise, Microvision's stock price hit our target. With another opportunity staring at us, we have decided to sell the remaining shares at $0.94. The total profit for the 2 months the shares were held was over 300%. This was not expected.

Proceeds will go to taxes, KeaneVCC charity, investors and the rest will be put back into the account.


   **All posts on this blog are information and opinions only. They are not to be considered recommendations to buy or sell any security. Please do your due diligence first before trading and investing. Please direct all questions and comments to the blog, kdkfund@gmail.com, or on twitter @kdkfund.

Portfolio Weekly Performance (Crispr, Microvision, Hive Blockchain, Social Capital)

Here are some metrics and some activity notes.

Security/Project	Type	Date of Purchase	Cost of Investment	Current Value	Return %	Notes
Crispr Therapeutics	Stock	3/23/2020	$38.78	54.01	39.27%
Microvision	Stock	3/23/2020	$0.00	0.44	100.00%	Sold Cost portion. All Profit at this point
Hive Blockchain	Stock	4/16/2020	$0.16	0.23	43.75%
Social Capital	Stock	5/1/2020	$10.20	10.19	-0.10%

- Crispr released earnings this past week. Story link can be found here.
- Sold 1/2 of Microvision stock. Story here.
- Microvision releasing earnings this week. 
- Bought Social Capital. Story here. 



 **All posts on this blog are information and opinions only. They are not to be considered recommendations to buy or sell any security. Please do your due diligence first before trading and investing. Please direct all questions and comments to the blog, kdkfund@gmail.com, or on twitter @kdkfund.

New Position in Social Capital

A new position has been started in Social Capital (symbol IPOB.U). The fund paid $10.20 for each unit. There is no plan to sell the stake and a strong motivation to keep adding to the position.

Social Capital's mission is "to advance humanity by solving the world’s hardest problems". Who doesn't like that mission ;)? In some seriousness, they are a driven company with an exceptional CEO (Samath Palihapitiya). The market value of the companies they invest in have yet to be quantified. KDK Fund expects this stake to keep producing positive results (financial and otherwise) for decades to come.  Their website can be found here.


**All posts on this blog are information and opinions only. They are not to be considered recommendations to buy or sell any security. Please do your due diligence first before trading and investing. Please direct all questions and comments to the blog, kdkfund@gmail.com, or on twitter @kdkfund.

1/2 Position in Microvision Sold

The fund has sold 1/2 of its position in Microvision. Some of the reasons are below.

- The price of Microvision rose to $0.40.
- Selling 1/2 the position protects capital, leaving the rest as profit
- There are other opportunities for the capital



**All posts on this blog are information and opinions only. They are not to be considered recommendations to buy or sell any security. Please do your due diligence first before trading and investing. Please direct all questions and comments to the blog, kdkfund@gmail.com, or on twitter @kdkfund.